Epcoritamab + R-DHAX/C in transplant-eligible patients (pts) with high-risk relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

• DOI: 10.1200/jco.2024.42.16_suppl.7032
• Publication Date: 2024-06-10T18:36:51Z
• Authors: Yasmin Karimi; Pau Abrisqueta; Sven de Vos; Marcel Nijland; Fritz Offner; Kojo Osei-Bonsu; Ali Rana; Kimberly G. Archer; Yaou Song; Raul Cordoba; Lorenzo Falchi
• Keywords: Refractory (planetary science)

7032 Background: While high-dose therapy (HDT)–autologous stem cell transplant (ASCT) is potentially curative for pts with R/R DLBCL, many do not receive this treatment (tx) due to insufficient response salvage chemoimmunotherapy; better options are needed. Epcoritamab a CD3xCD20 bispecific antibody efficacy and safety in DLBCL as single agent combination. We report updated data from epcoritamab combination rituximab, dexamethasone, cytarabine, oxaliplatin or carboplatin (R-DHAX/C) eligible HDT-ASCT, including high-risk (progressed within 12 mo of initial tx primary refractory), EPCORE™ NHL-2 (phase 1/2; NCT04663347). Methods: Adults CD20 + HDT-ASCT received R-DHAX/C (2 step-up doses, then 24- 48-mg full doses) 21-d cycles (Cs): QW, C1–3. If was deferred, could continue (21-d C: C4; 28-d Cs: Q2W, C5–9; Q4W, C≥10) until disease progression. Primary endpoint overall rate (ORR; Lugano criteria). Results: As Dec 15, 2023, 29 (median age, 58 y) (24 mg, n=3; 48 n=26) R-DHAX/C. At baseline, 24 (83%) had progressed tx, 19 (66%) refractory (no relapse 6 tx), 3 (10%) prior CAR T. 27.5 median follow-up, 16 (55%) proceeded 2 (7%) remained on tx. ORR 76% complete (CR) 69% (Table). Median time 1.4 (CR, 1.5 mo). mo, per Kaplan–Meier estimates, 60% progression free, while 90% who ASCT (n=16) continued without (n=5) free; additionally, CR (n=15) 100% (n=12) response. An estimated 86% alive at mo. The most common tx-emergent AEs (TEAEs) any grade (G) were thrombocytopenia (76%), anemia (59%), nausea (48%), neutropenia (48%; febrile neutropenia, 17%). CRS low (38% G1, 7% G2), resolved, did lead discontinuation. ICANS (G2) occurred 1 pt led There no fatal TEAEs. Conclusions: Longer follow-up reaffirms the feasibility ASCT-eligible DLBCL. Response rates high ASCT. Safety manageable consistent data. These results, new subgroup analyses, support future evaluation Clinical trial information: NCT04663347 . [Table: see text]